Welcome to our dedicated page for PHARMAGREEN BIOTECH news (Ticker: PHBI), a resource for investors and traders seeking the latest updates and insights on PHARMAGREEN BIOTECH stock.
Pharmagreen Biotech Inc. is a biotech sciences solutions company based in Coquitlam, Canada, specializing in producing starter plantlets for the CBD hemp and medical cannabis industries. The company is focused on developing organic formulations based on mushrooms and therapeutic plants, expanding through white labeling services and industry mergers/acquisitions. Pharmagreen's innovative approach includes nutraceutical products using plant genetics technology to research and create supplements for various health conditions.
The company's major achievement includes being approved for online sales via Amazon's e-commerce platform for their MaxGenomicTM Supplement and securing the use of SierraSil® minerals in their formulations. Pharmagreen is also working on developing pre-workout formulas, gummy products, and looking to achieve positive cash flow by year-end.
Pharmagreen Biotech, Inc. (OTCQB: PHBI) is advancing its acquisition of Long Valley Farms (LVF), which is applying for crucial licenses to operate in cultivation, manufacturing, and retail. LVF is preparing to plant 1,200 cannabis plants, with harvest expected in 45-60 days. The company focuses on proprietary therapeutic cannabis strains intended for live rosin production, aiming to maximize cannabinoid and terpene profiles. This acquisition aligns with Pharmagreen's strategy to leverage its cannabis tissue culture technology, Chibafreen, as a key revenue source.
Pharmagreen Biotech, Inc. (OTCQB: PHBI) announces progress on its acquisition of Long Valley Farms, making a significant payment to fully clear a 12-acre property. This move secures the land for its cannabis cultivation operations and licenses under California's legacy system amidst impending regulatory changes. The acquisition aligns with Pharmagreen’s vertical growth strategy to monetize its proprietary cannabis tissue culture technology, Chibafreen, while the company continues to apply for additional cannabis licenses and construct IoT greenhouses.
Pharmagreen Biotech, Inc. (OTCQB: PHBI) announced a memorandum of understanding to acquire Long Valley Farms LLC, a California cannabis company. This acquisition encompasses land, infrastructure, and a cannabis cultivation license. It aims to leverage Pharmagreen's proprietary cannabis tissue culture technology, Chibafreen, to generate revenue. Long Valley Farms plans to apply for additional cannabis licenses immediately. The MOU is an affirmation of the prior agreement from July 2021. CEO Ethan Styles emphasizes the strategic potential of this acquisition to enhance market share in California's evolving cannabis industry.
Pharmagreen Biotech (OTCQB: PHBI) confirmed a memorandum of understanding (MOU) to acquire California-based Long Valley Farms LLC, including its land, infrastructure, and cannabis cultivation license. This strategic acquisition aims to leverage Pharmagreen’s proprietary cannabis tissue culture technology, Chibafreen, into realized revenue. Long Valley Farms plans to apply for multiple cannabis licenses in California. This MOU expands upon a prior agreement from July 2021, committing Pharmagreen to cover ongoing operational costs related to Long Valley Farms.
Pharmagreen Biotech (OTCQB: PHBI) announced the approval of its application to up-list from OTC Pinks to OTCQB, effective December 20, 2021. The OTCQB is a notable marketplace for entrepreneurial companies emphasizing transparency and quality trading experiences. CEO Peter Wojcik highlighted that this upgrade is crucial for investor confidence, especially in the complex cannabis industry. Additionally, Pharmagreen initiated a crowdfunding campaign on DealMaker, offering shares under a Regulation A offering qualified in September 2021, further expanding its capital-raising options.
Pharmagreen Biotech Inc. (OTCQB: PHBI) has successfully gained approval for its application to the OTCQB Venture Market, enhancing its visibility among investors. The OTCQB is designed for growth-oriented companies, ensuring transparency and compliance through rigorous standards. CFO Peter Wojcik emphasized the importance of transparency in the cannabis industry. Additionally, Pharmagreen has initiated a crowdfunding campaign on DealMaker to raise up to $7.5 million, selling units at $0.025 each for the acquisition of a cannabis company and the construction of a state-of-the-art greenhouse.
Pharmagreen Biotech, Inc. (OTC PINK: PHBI) is advancing its proprietary cannabis tissue culture technology into a revenue-generating operation, as announced by CEO Peter Wojcik. The company is nearing completion of its application for an up-listing to the OTCQB Venture Market, enhancing compliance and transparency for investors. Additionally, Pharmagreen is finalizing an acquisition of a California cannabis enterprise, including essential licenses and infrastructure. Regular updates will be provided to stakeholders as the company transitions its technology into a source of recurring revenue.
Pharmagreen Biotech (OTC PINKS: PHBI) released a management update from CEO Peter Wojcik on its strategy to monetize its proprietary Chibafreen tissue culture technology. This technology aims to enhance cannabis production efficiency while maintaining genetic purity. Wojcik emphasizes the importance of a strong executive team, including COO Dr. Fawzia Afreen and CFO Terry Kwan, in executing the business strategy. The company plans to provide further updates to shareholders and aims to establish Chibafreen as an industry standard in cannabis cultivation.
Pharmagreen Biotech, Inc. (OTC PINK: PHBI) released a management update from CEO Peter Wojcik outlining the company's strategy to monetize its proprietary tissue culture technology, Chibafreen. This technology aims to enhance scalability and genetic purity in cannabis cultivation. The executive team, including COO Dr. Fawzia Afreen and CFO Terry Kwan, is positioned to drive growth and transition Chibafreen into a recurring revenue source. Future updates to shareholders are anticipated to further clarify the strategy and execution.
Pharmagreen Biotech (OTC Pink: PHBI) has announced a strategic update from CEO Peter Wojcik regarding the company's plans to leverage its proprietary Chibafreen tissue culture process for revenue generation. The process aims to supply genetically identical and disease-free cannabis starter plantlets, enhancing scalability in the cannabis industry. A 12,000 square foot IoT-enabled greenhouse in Northern California is central to this strategy, potentially generating $10 million annually in cash flow. Pharmagreen anticipates revenue generation starting in 2022, with further growth expected over five years.
FAQ
What is the current stock price of PHARMAGREEN BIOTECH (PHBI)?
What is the market cap of PHARMAGREEN BIOTECH (PHBI)?
What does Pharmagreen Biotech Inc. specialize in?
Where is Pharmagreen Biotech Inc. headquartered?
What recent achievement has Pharmagreen Biotech Inc. made?
What is Pharmagreen Biotech Inc.'s long-term focus?
What is Pharmagreen Biotech Inc.'s innovative approach?
What are some of the products Pharmagreen Biotech Inc. is developing?
